Genmab — Januar 2016
-
Gilead - ny ceo og nede med 5%. Det er sgu festlige tider...
-
Immunogen earnings og nede med 8%
-
A pro pos Gilead:
http://seekingalpha.com/article/3846896-buy-biotech-sell -
sjovt nok er Gilead altid top pick - men de kan sgu ikke rigtigt komme ud over rampen
-
De hænger fast i en lav P/E
-
hold nu kæft, hvor er de skizofrene derovre - index ned med over-1% og nu oppe med over 1,5%. På 20 minutter
-
Den type volatilitet gør mig altid noget nervøs omkring den overordnede retning
-
jep - når det er sådan, foretrækker jeg at være helt oppe på tæerne
-
EMA-godkendelsen kan komme i ekspresfart "Darzalex was also on this week’s CHMP agenda for adoption of 120-day questions and, according to the accelerated procedure, there will be a CHMP opinion after just 150 days (instead of 210). Hence, there could be an opinion for Darzalex already at the next CHMP meeting (end February), meaning a potential launch of Darzalex in Q2 as well, or at least no later than the summer 2016. We have a Buy on Genmab with a target price of DKK 1,100 per share."
-
jeg tror stadig, vi er on-track til godkendelse "før sommer". Så dagens minutes fra chmp er blot bekræftigelse af, at alt kører som skitseret tilbage i september ifm accelerated approval
-
Det bliver lidt spændende om castor og pollux (insh allah) også bliver accelerated approval - de kommer jo i konkurrence med elo
-
Godt at sove på.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind